Q3 2025 EPS Estimates for Aurora Cannabis Inc. Raised by Roth Capital (TSE:ACB)

Aurora Cannabis Inc. (TSE:ACB) – Roth Capital raised their Q3 2025 earnings per share (EPS) estimates for shares of Aurora Cannabis in a research report issued to clients and investors on Wednesday, August 7th. Roth Capital analyst W. Kirk now anticipates that the company will earn $0.00 per share for the quarter, up from their prior forecast of ($0.13). The consensus estimate for Aurora Cannabis’ current full-year earnings is ($0.22) per share. Roth Capital also issued estimates for Aurora Cannabis’ Q4 2025 earnings at $0.05 EPS.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Thursday, June 20th. The company reported C$0.14 EPS for the quarter, beating the consensus estimate of C($0.24) by C$0.38. The company had revenue of C$67.41 million during the quarter, compared to the consensus estimate of C$69.30 million. Aurora Cannabis had a negative return on equity of 10.51% and a negative net margin of 24.26%.

Separately, ATB Capital cut their price objective on Aurora Cannabis from C$12.50 to C$11.00 and set a “sector perform” rating for the company in a report on Friday, June 21st.

Aurora Cannabis Trading Up 0.2 %

TSE ACB opened at C$8.88 on Monday. The company has a market cap of C$484.40 million, a PE ratio of -6.94 and a beta of 2.72. The company has a current ratio of 3.42, a quick ratio of 2.48 and a debt-to-equity ratio of 17.41. Aurora Cannabis has a 12 month low of C$3.84 and a 12 month high of C$15.50. The stock has a 50 day moving average of C$7.80 and a 200-day moving average of C$6.73.

About Aurora Cannabis

Aurora Cannabis Inc, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products.